- Recce Pharmaceuticals (RCE) updates its clinical timeline, with several data read-outs expected over this year and next year
- The company expects to dose its first subject under a phase 1b/2a multi-dose and early-stage sepsis study later this year
- Meanwhile, new data from antoher phase one clinical trial of R327 supports findings from pre-clinical in-vivo kidney and UTI bacterial infection studies
- Furthermore, Recce has designed a new phase two study for R327 for treating diabetic foot ulcer infections, with the first patient to be dosed before the end of the year
- Shares in Recce Pharmaceuticals are trading 6.15 per cent higher at 69 cents each at 2:59 pm AEST
Recce Pharmaceuticals (RCE) has updated its clinical timeline, with several data read-outs expected over this year and next year.
The company expects to dose its first subject under a phase 1b/2a multi-dose and early-stage sepsis study later this year.
Meanwhile, new data from a phase one clinical study of R327 in treating urinary tract infections (UTIs) has supported findings from pre-clinical in-vivo kidney and UTI bacterial infection studies.
Reece said the patients dosed with R327 had high concentrations of the drug in their urine, suggesting opportunities for therapeutic activity in the human urinary tract.
It is now finalising the study protocol for a phase two clinical trial, with the first patient under the study expected to be dosed early next year.
Furthermore, Recce has designed a new phase two study for R327 treating diabetic foot ulcer infections, with the first patient to be dosed in the fourth quarter of this year.
Finally, Recce said it had also progressed multiple pre-clinical programs to advanced stages.
CEO James Graham said Recce had developed an “ambitious” development plan to get new anti-infective therapies into the market as soon as possible.
“With good safety and encouraging signs of efficacy, we look ahead to new indications that can best adapt to physician and patient needs,” he said.
Shares in Recce Pharmaceuticals were trading 6.15 per cent higher at 69 cents each at 2:59 pm AEST.